Mechanism of action
Semaglutide copies the gut hormone GLP-1 (see GLP-1 receptor agonist). Its structure was changed so it binds to a blood protein called albumin, which keeps it in the body for about a week. It raises insulin when blood sugar is high, slows stomach emptying and reduces appetite.
Approvals
The FDA approved semaglutide as Ozempic, a weekly injection for type 2 diabetes, in December 2017. The tablet Rybelsus followed in 2019. Wegovy, a higher-dose weekly injection for chronic weight management, was approved on June 4, 2021. On March 8, 2024, Wegovy became the first medicine approved to lower the risk of serious heart problems specifically in adults with obesity or overweight and heart disease. That approval was based on the SELECT trial, which enrolled 17,604 adults without diabetes. On August 15, 2025, Wegovy received accelerated approval for the liver disease MASH.
Wegovy was approved for adolescents aged 12 and older on December 23, 2022. On January 28, 2025, Ozempic was approved to lower the risk of kidney disease getting worse, kidney failure and heart death in adults with type 2 diabetes and chronic kidney disease, based on the FLOW trial.
A higher-dose daily tablet, the Wegovy pill, was approved on December 22, 2025, for weight management. The Wegovy injection label includes doses up to 7.2 mg once weekly.
Clinical trials
The weight-management approval rests on the STEP trials. In the STEP 1 trial, adults without diabetes on semaglutide 2.4 mg lost 14.9% of their body weight on average after 68 weeks, vs. 2.4% on placebo. In the OASIS 4 trial of the 25 mg tablet, the average loss was 13.6% after 64 weeks, vs. 2.4% on placebo.
In the semaglutide trial extension, people regained about two-thirds of the weight they had lost within a year of stopping.
Side effects and availability
The most common side effects of semaglutide are nausea, diarrhea, vomiting, constipation and stomach pain, mostly while the dose is being raised. The label has a boxed warning about thyroid C-cell tumors seen in rodents.
Brand-name semaglutide is sold by prescription at retail pharmacies and through online programs. Compounded semaglutide is prepared by state-licensed pharmacies for an individual prescription and is not an FDA-approved product. Online programs for both are compared on our compounded semaglutide page.
Timeline
- 2017-12-05Ozempic approved for type 2 diabetes
- 2019-09-20Rybelsus, the first GLP-1 tablet, approved for type 2 diabetes
- 2021-06-04Wegovy injection approved for chronic weight management
- 2022-12-23Wegovy approved for adolescents aged 12 and older
- 2024-03-08Wegovy approved to lower the risk of heart attack, stroke and heart death in adults with heart disease and obesity or overweight
- 2025-01-28Ozempic approved to lower kidney and heart risks in type 2 diabetes with chronic kidney disease
- 2025-08-15Wegovy approved for MASH with moderate to advanced liver scarring
- 2025-12-22Wegovy pill approved for weight management
See also
References
- Wegovy prescribing information, DailyMed (revised 2026). dailymed.nlm.nih.gov
- FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight (FDA, March 8, 2024). fda.gov
- FDA approves treatment for serious liver disease known as MASH (FDA, August 15, 2025). fda.gov
- Wilding et al., NEJM 2021 (STEP 1). nejm.org
- Wegovy prescribing information 2026 (OASIS 4). accessdata.fda.gov
- Wilding et al., Diabetes Obes Metab 2022 (STEP 1 extension). doi.org
Last updated . Category: Medications. Browse all 38 WikiTelehealth entries.